Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The decision is based on the phase 3 DESTINY-Breast11 trial
Subscribe To Our Newsletter & Stay Updated
